- Home
- RXST vs ADPT Comparison
RXST vs ADPT Comparison
Compare RXST & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXST
- ADPT
- Stock Information
- Founded
- RXST 1997
- ADPT 2009
- Country
- RXST United States
- ADPT United States
- Employees
- RXST N/A
- ADPT N/A
- Industry
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXST Health Care
- ADPT Health Care
- Exchange
- RXST Nasdaq
- ADPT Nasdaq
- Market Cap
- RXST 1.0B
- ADPT 1.1B
- IPO Year
- RXST 2021
- ADPT 2019
- Fundamental
- Price
- RXST $13.06
- ADPT $9.03
- Analyst Decision
- RXST Buy
- ADPT Buy
- Analyst Count
- RXST 10
- ADPT 6
- Target Price
- RXST $38.50
- ADPT $9.83
- AVG Volume (30 Days)
- RXST 1.1M
- ADPT 3.0M
- Earning Date
- RXST 05-07-2025
- ADPT 05-01-2025
- Dividend Yield
- RXST N/A
- ADPT N/A
- EPS Growth
- RXST N/A
- ADPT N/A
- EPS
- RXST N/A
- ADPT N/A
- Revenue
- RXST $148,310,000.00
- ADPT $189,527,000.00
- Revenue This Year
- RXST $24.14
- ADPT $21.20
- Revenue Next Year
- RXST $21.47
- ADPT $21.99
- P/E Ratio
- RXST N/A
- ADPT N/A
- Revenue Growth
- RXST 46.70
- ADPT 8.61
- 52 Week Low
- RXST $13.50
- ADPT $2.99
- 52 Week High
- RXST $66.54
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- RXST 32.41
- ADPT 57.82
- Support Level
- RXST $13.72
- ADPT $8.38
- Resistance Level
- RXST $15.41
- ADPT $9.51
- Average True Range (ATR)
- RXST 0.90
- ADPT 0.66
- MACD
- RXST 0.28
- ADPT 0.16
- Stochastic Oscillator
- RXST 1.00
- ADPT 63.02
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).